Marker Therapeutics, Inc.
MRKRAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| WBB Securities | maintain | Strong Buy | Apr 1, 2025 |
| Roth Capital | downgrade | Buy →Neutral | Feb 17, 2022 |
| Piper Sandler | downgrade | Overweight →Neutral | May 12, 2020 |
| Piper Jaffray | maintain | Overweight | Nov 13, 2019 |
| Janney Capital | maintain | Buy | Nov 13, 2019 |
| WBB Securities | upgrade | Buy →Strong Buy | Mar 29, 2019 |
Earnings History
Next report: Mar 24, 2027 · EPS est. $-0.22| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.09 | $-0.13 | $700.0K | $660.7K |
| May 15, 2026 | $-0.16 | $-0.18 | $800.0K | $783.9K |
| Mar 18, 2026 | $-0.10 | $-0.21 | $1.1M | $682.1K |
| Nov 13, 2025 | $-0.12 | $-0.36 | $1.2M | $723.0K |
| Aug 14, 2025 | $-0.29 | $-0.30 | $861.2K | $430.6K |
| May 15, 2025 | $-0.40 | $-0.66 | $349.1K | $174.6K |
| Mar 31, 2025 | $-0.42 | $-0.22 | $2.3M | $1.2M |
| Nov 14, 2024 | $-0.26 | $-0.39 | $1.9M | $1.0M |
News
HOUSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), is a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies under an exclusive worldwide license from Baylor College of Medicine for patients with cancer. Today, Marker announced that the Company has been awarded $2.6 million from the U.S. Food and Drug Administration (FDA) through its Orphan Products Clinical Trials grants program.
MARKER THERAPEUTICS (MRKR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
UGP, SCSC, MRKR, SLGL and MEOH have been added to the Zacks Rank #1 (Strong Buy) List on October 16, 2026.
HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for the treatment of hematologic malignancies and solid tumors, today highlighted the expanded infrastructure, technical expertise and manufacturing capabilities supporting its lead program, MT-601 (neldaleucel), following the combination of Cellipont Bioservices and Kincell Bio to form Kincellis Advanced Therap…